SCHEMBL2366142

SCHEMBL2366142

COCC1COC(=O)N1c1ccc(C(=O)N2CCN(C(=O)OC(C)(C)C)CC2)cc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.48
MEN1 O00255 4/20 0.48
HDAC4 P56524 1/20 0.43
ALDH1A1 P00352 2/20 0.43
ABL1 P00519 1/20 0.42
RIN1 Q13671 1/20 0.42
EPHX2 P34913 1/20 0.42
GPR119 Q8TDV5 3/20 0.41
GAA P10253 2/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
LMNA P02545 2/20 0.40
MAPT P10636 2/20 0.40
SETD7 Q8WTS6 1/20 0.40
NPC1L1 Q9UHC9 2/20 0.39
CYP2C19 P33261 1/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CNR2 P34972 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2366137 1.00 KMT2A (0.48) KMT2AMEN1HDAC4ALDH1A1ABL1
SCHEMBL2366528 0.91 KMT2A (0.47) KMT2AMEN1HDAC4ALDH1A1ABL1
SCHEMBL2366525 0.91 KMT2A (0.47) KMT2AMEN1HDAC4ALDH1A1ABL1
SCHEMBL2366680 0.90 KMT2A (0.50) KMT2AMEN1HDAC4ALDH1A1ABL1
SCHEMBL2366683 0.90 KMT2A (0.50) KMT2AMEN1HDAC4ALDH1A1ABL1
SCHEMBL2366863 0.87 ALDH1A1 (0.47) KMT2AMEN1HDAC4ALDH1A1ABL1
SCHEMBL2366857 0.87 ALDH1A1 (0.47) KMT2AMEN1HDAC4ALDH1A1ABL1
SCHEMBL2366939 0.86 CPS1 (0.41) GPR119LMNAMAPTSETD7
SCHEMBL2366957 0.86 CPS1 (0.41) GPR119LMNAMAPTSETD7
SCHEMBL2365768 0.85 L3MBTL1 (0.42) KMT2AMEN1HDAC4ALDH1A1GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2364975-B1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORP (JP) 2013-06-12 EP disclosed
US-8354401-B2 Oxazolidinone amide aromatic compounds for supressing MMP-9 production MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-01-15 US disclosed
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-10-27 US disclosed
EP-2364975-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2011-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP2 KMT2A 800/4885MEN1 2896/4885HDAC4 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.